Form 4: Ionis CBO Baroldi Granted Stock Options

Ionis Pharmaceuticals' Chief Business Officer, Joseph Baroldi, was granted non-qualified stock options for 21,950 shares, including options for his spouse, under the company's equity incentive plan.

Summary

• Joseph Baroldi, EVP, Chief Business Officer of Ionis Pharmaceuticals Inc. (IONS), was granted non-qualified stock options.
• The options were granted on January 2, 2026, with an exercise price of $79.67 per share.
• A direct grant to Mr. Baroldi consists of 19,350 options to buy common stock.
• An indirect grant to Mr. Baroldi's spouse consists of 2,600 options to buy common stock.
• The total number of options granted is 21,950.
• The options were granted under the Ionis Pharmaceuticals, Inc. Amended and Restated 2011 Equity Incentive Plan.
• The options begin vesting on January 2, 2027, with 25% of shares becoming exercisable.
• The remaining shares will vest in 36 equal monthly installments over the subsequent three years.
• The expiration date for these options is January 1, 2036.

Sentiment

Score: 5

Explanation: This Form 4 filing is a routine disclosure of an executive stock option grant and does not contain information that would significantly alter the company's perceived financial health or operational outlook. It is a neutral event from a sentiment perspective.

Positives

• The grant of stock options aligns the interests of the Chief Business Officer with those of shareholders, incentivizing long-term company performance.
• The options are part of a structured equity incentive plan, indicating a standard approach to executive compensation.

Negatives

• No direct negative financial or operational information is contained within this Form 4 filing.

Risks

• No specific risks are mentioned in this transactional Form 4 filing.

Future Outlook

The options are subject to a vesting schedule, with 25% becoming exercisable on January 2, 2027, and the remainder vesting in 36 equal monthly installments over the subsequent three years, indicating a long-term incentive structure.

Industry Context

The grant of stock options to a senior executive is a common practice in the biotechnology and pharmaceutical industry, used to attract, retain, and incentivize key talent by aligning their financial interests with the long-term performance of the company and its shareholders.

Comparison to Industry Standards

• The use of non-qualified stock options with a multi-year vesting schedule is a standard component of executive compensation packages across the pharmaceutical and biotech sectors, comparable to practices at companies like Amgen, Gilead Sciences, or Biogen, which frequently utilize equity incentives to motivate leadership.
• The specific exercise price and number of options are tailored to the individual's role and company-specific compensation policies, but the structure is consistent with industry benchmarks for aligning executive and shareholder interests.

Corporate Governance

Related Party Transactions

• An indirect grant of 2,600 non-qualified stock options was made to Joseph Baroldi's spouse, which is disclosed as a related party transaction.

Stakeholder Impact

• Shareholders: The grant of options aims to align the Chief Business Officer's long-term financial interests with shareholder value creation.
• Employees: This filing specifically pertains to an executive, but the underlying equity incentive plan may also apply to other employees, contributing to overall employee retention and motivation.

Next Steps

• The options will begin their vesting schedule on January 2, 2027, with subsequent monthly vesting installments over the following three years.

Key Dates

Keywords

Ionis Pharmaceuticals, IONS, Joseph Baroldi, stock options, executive compensation, Form 4, insider transaction, equity incentive plan, non-qualified stock option, CBO